shares of spectrum pharmaceuticals inc sppi were down 220 in premarket trading on friday the day after a food and drug administration committee voted 94 that the benefits of the companys experimental lungcancer drug do not outweigh the risks the fda is not required to follow the committees advice when deciding when to approve a new drug but often does the regulator is expected to make its decision on or before nov 24 spectrum on friday also announced a fiveyear debt financing plan with slr capital partners for up to 65 million the company said the deal along with its existing cash balance will support the commercial launch of roldvedon a treatment for chemotherapyinduced neutropenia that received fda approval this month and fund operations through 2024 spectrums stock is down 492 this year while the broader sp 500 spx has declined 205